ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 121 citations in OpenAlex.
- Intratumoral Fusogenic Outer Membrane Vesicles Enhance Antitumor Immunity Through Tumor MHC-I Upregulation and Tumor Bacterization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions.Journal of advanced research · 2026Review
- Artificial "zombie" cells: An emerging platform for targeted drug delivery and disease treatment.Acta pharmaceutica Sinica. B · 2026Review
- Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Versatile Co-Engineering of Immunogenic Cell Death-Primed Dead Tumor Cell Bodies With Tumor-Activated MnOAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in Therapeutic Melanoma Vaccines (2010-2025).Vaccines · 2026Review
- Designing lysate-based hydrogels for on-demand therapy.Journal of pharmaceutical analysis · 2026Review
- Irradiated Liver Cancer Cell Vaccine Transfected With GM-CSF Induces Specific and Long-Lasting Anti-tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM-CSF.Cell proliferation · 2026Article
- RHOT1/2-driven mitochondrial membrane vesicles confer tumor-homing selectivity and enable in situ cancer vaccination.Nature communications · 2026Article
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Bacterialized tumor cells as vaccine.EMBO molecular medicine · 2026Article
- Mucoadhesive oral nanovaccine delivery system with immunomodulatory capacity for synergistic colorectal cancer therapy.Materials today. Bio · 2026Article
- Vaccine-expanded plasmablast-like B cells are associated with response to dendritic cell therapy in metastatic melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Adjuvant choice shapes macrophage activation and cytokine responses to freeze-thaw breast cancer antigens.BMC research notes · 2026Article
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- Dendritic cell-derived exosomes from PDT-treated glioma cells enhance antitumor immunity as a subcellular vaccine.Journal of translational medicine · 2026Article
- Oocyte-inspired universal whole-cell vaccines against tumor heterogeneity.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells.ACS materials letters · 2026Article
- Redefining Dendritic Cell Vaccines: Synergistically Co-priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Endogenous living adjuvants for cancer vaccination: Concepts, mechanisms, and design principles.Materials today. Bio · 2026Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancer immunotherapies have improved human health, and one among the important technologies for cancer immunotherapy is cancer vaccine. Antigens are the most important components in cancer vaccines. Generally, antigens in cancer vaccines can be divided into two categories: pre-defined antigens and unidentified antigens. Although, cancer vaccines loaded with predefined antigens are commonly used, cancer vaccine loaded with mixed unidentified antigens, especially whole cancer cells or cancer cell lysates, is a very promising approach, and such vaccine can obviate some limitations in cancer vaccines. Their advantages include, but are not limited to, the inclusion of pan-spectra (all or most kinds of) antigens, inducing pan-clones specific T cells, and overcoming the heterogeneity of cancer cells. In this review, the recent advances in cancer vaccines based on whole-tumor antigens, either based on whole cancer cells or whole cancer cell lysates, are summarized. In terms of whole cancer cell lysates, the focus is on applying whole water-soluble cell lysates as antigens. Recently, utilizing the whole cancer cell lysates as antigens in cancer vaccines has become feasible. Considering that pre-determined antigen-based cancer vaccines (mainly peptide-based or mRNA-based) have various limitations, developing cancer vaccines based on whole-tumor antigens is a promising alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.